Scientists have identified specific genetic variations that predict how well GLP-1 medications will work for individual patients, potentially allowing doctors to personalize obesity treatment before people start taking these drugs. A landmark study of nearly 28,000 people published in Nature found that genetic differences in the GLP-1 receptor gene can determine whether someone loses an extra 0.76 kilograms or experiences debilitating nausea, suggesting that one-size-fits-all prescribing may soon become outdated .

Why Do Some People Respond Dramatically to GLP-1 Drugs While Others Don't?

When GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) first became widely available, doctors noticed something puzzling: the same dose produced wildly different results. In clinical trials, some patients lost over 25% of their body weight, while others lost less than 5% or gained weight. For nearly two decades, researchers couldn't explain why .

The 23andMe Research Institute set out to answer this question by surveying over 27,885 people who had used GLP-1 medications and comparing their experiences to their genetic data. The study participants were mostly female (82.4%), with a median age of 52 years, and had a starting body mass index (BMI) of 35.1 kg/m² (roughly 245 pounds for someone 5'10"). After taking GLP-1 drugs for a median of 8.3 months, participants lost an average of 11.7% of their pre-treatment weight, but the range was enormous .

The researchers conducted a genome-wide association study, scanning millions of genetic variants to find which ones correlated with treatment outcomes. The strongest signal came from a specific variant in the GLP1R gene, which encodes the GLP-1 receptor itself, the very target these drugs are designed to activate. People carrying the effect allele lost an additional 0.76 kilograms compared to those without it .

"It made very clear biological sense. This is the receptor that the drug is acting on," explained Adam Auton, Vice President of Human Genetics at the 23andMe Research Institute.

Adam Auton, Vice President of Human Genetics, 23andMe Research Institute

The genetic variant may affect how much GLP-1 receptor is expressed on the surface of cells. If someone has more receptors, the same dose of medication has more targets to bind to, potentially creating a stronger response. This finding suggests that genetic testing could eventually help doctors predict who will benefit most from GLP-1 therapy before they start treatment .

What About Side Effects? Can Genetics Predict Nausea and Vomiting?

Weight loss is only part of the story. Many people stop taking GLP-1 drugs because of side effects, particularly nausea and vomiting, which can be severe enough to interfere with daily life. The 23andMe study identified a second genetic variant, this time in the GIPR gene, that predicted who would experience these gastrointestinal problems .

The twist: this variant only affected people taking tirzepatide, the dual GLP-1 and GIP receptor agonist. People taking semaglutide, which targets only the GLP-1 receptor, showed no increased nausea risk from the GIPR variant. This specificity suggests that genetic effects are highly drug-dependent, meaning the same genetic variant can have completely different consequences depending on which medication someone takes .

"It was very, very clean. We saw this effect specifically in people taking the medications that actually target that receptor," noted Auton.

Adam Auton, Vice President of Human Genetics, 23andMe Research Institute

The researchers validated their findings by comparing self-reported data with electronic health records from a subset of participants. The results were reassuring: survey-reported weight loss closely matched medical records, and the genetic associations remained robust even when tested against independent datasets .

How to Prepare for Personalized GLP-1 Treatment

• Discuss genetic testing with your doctor: While genetic testing for GLP-1 response is not yet standard clinical practice, ask your healthcare provider whether they anticipate offering pharmacogenetic testing in the future, as this field is rapidly evolving.
• Track your personal response carefully: Keep detailed notes on weight loss, side effects, and how you feel on your current dose, since individual variation is substantial and your doctor may need to adjust your medication or dosage based on your specific experience.
• Be honest about side effects: Don't assume nausea, vomiting, or other gastrointestinal symptoms are just "part of the deal." These could indicate that a different medication or dose might work better for your genetic profile.
• Understand that ancestry matters: The study found that GLP-1 medications were most effective in people of European ancestry, less effective in people of Latino ancestry, and least effective in people of African American ancestry, suggesting that treatment responses vary by genetic background.

What Does This Mean for the Future of Obesity Treatment?

The healthcare system is struggling to keep up with the explosive demand for GLP-1 drugs. Millions of Americans are now taking these medications, often obtained through online telehealth services with minimal medical oversight. Yet fundamental questions remain unanswered: why do some people respond so robustly while others barely benefit? Why do side effects cluster so differently? And what happens after 10, 15, or 20 years of continuous use ?

The 23andMe findings suggest that precision medicine could be part of the answer. If doctors could identify patients most likely to respond well and tolerate treatment before they start, they could optimize drug selection, dosage, and titration schedules. This could reduce wasted prescriptions, minimize unnecessary side effects, and improve long-term adherence .

However, experts caution that genetic testing alone won't solve all the challenges. Non-genetic factors also matter significantly. The study found that medication efficacy depended strongly on sex, drug type, time on treatment, and drug dosage. Women experienced greater weight loss than men (12.2% versus 10.0% BMI reduction), and tirzepatide produced larger BMI reductions than semaglutide (4.75 versus 3.71 kg/m²), despite similar treatment durations .

Age also played a role: each additional 10 years of age corresponded to about a 0.5% reduction in BMI change, or roughly 0.45 kilograms less weight loss. Type 2 diabetes status was another major predictor; people with diabetes lost about 2.87 percentage points less BMI than those without diabetes, likely because these drugs were originally developed for blood sugar control rather than weight loss alone .

"These drugs affect receptors all over the body. You shouldn't feel terrible and assume that's just the deal. That could be something serious," warned Jody Dushay, an endocrinologist at Beth Israel Deaconess Medical Center.

Jody Dushay, Endocrinologist, Beth Israel Deaconess Medical Center

The bigger picture is that GLP-1 medications are being used at a population scale while fundamental questions remain unanswered. The 23andMe study represents a major step toward understanding individual variation, but it also highlights how much work remains. As these drugs become even more accessible, with new oral formulations like Foundayo now approved by the FDA, the need for personalized guidance becomes more urgent .

For now, the takeaway is clear: your genes matter, but they're only part of the story. A combination of genetic testing, careful monitoring of your personal response, honest communication with your healthcare provider about side effects, and realistic expectations about long-term use will likely offer the best path forward as precision obesity medicine develops .